Gradalis's phase 2 results due early next year. By then we should get more information from Standford's preclinical trials with the pain program. If we get good news from Stanford plus licensing from Gradalis, I wonder what the sp will be like.
BLT Price at posting:
45.0¢ Sentiment: LT Buy Disclosure: Held